[{"orgOrder":0,"company":"Halozyme Therapeutics","sponsor":"Horizon Therapeutics","pharmaFlowCategory":"D","amount":"$190.0 million","upfrontCash":"$30.0 million","newsHeadline":"Horizon Therapeutics plc and Halozyme Therapeutics, Inc. Enter Global Collaboration and License Agreement for ENHANZE\u00ae Technology","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase IV","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Collaboration","leadProduct":"Teprotumumab","moa":"IGF-1R","url1":"","url2":"","graph1":"Immunology","graph2":"Phase IV","graph3":"Halozyme Therapeutics","amount2":0.19,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.19,"dosageForm":"Intravenous Injection","sponsorNew":"Halozyme Therapeutics \/ Horizon Therapeutics","highestDevelopmentStatusID":"11","companyTruncated":"Halozyme T.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer Shares Co-Primary Endpoint Results from Post-Marketing Required Safety Study of Xeljanz\u00ae in Rheumatoid Arthritis Patients","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase IV","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","url1":"","url2":"","graph1":"Immunology","graph2":"Phase IV","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Health Canada has Initiated a Safety Review On Xeljanz and Xeljanz XR (Tofacitinib), Used to Treat Arthritis and Ulcerative Colitis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase IV","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","url1":"","url2":"","graph1":"Immunology","graph2":"Phase IV","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Pfizer Inc.."}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Weekly News Recap
#Phispers

Stock Recap
#PipelineProspector

Filters

×

filter

Company Name

filter

Year

filter

DEALS // DEV.

filter

Country

filter

Sponsor

filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

All Developments

Therapeutic Area by Lead Product

Study Phase by Lead Product

Company by Lead Product

Top Deals by Deal Size (USD bn)

Reset All

01

Samsung Bioepis

South Korea

26th North American ISSX

Not Confirmed

02

Horizon Therapeutics

Ireland

26th North American ISSX

Not Confirmed

03

Johnson & Johnson Innovative Medicine

U.S.A

26th North American ISSX

Not Confirmed

04

Horizon Therapeutics

Ireland

26th North American ISSX

Not Confirmed

05

Eli Lilly

U.S.A

26th North American ISSX

Not Confirmed

06

Pfizer Inc

U.S.A

26th North American ISSX

Not Confirmed

07

Pfizer Inc

U.S.A

26th North American ISSX

Not Confirmed